NetworkNewsWire Announces Publication Outlining In

NEW YORK, NY--(Marketwired - Nov 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. ( CSE : IN ) ( OTCQB : IMLFF ), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.

The publication, titled, "Innovation Drives Value for Leading Cannabis Biotechs," features the work several biotech companies are pursuing to advance their R&D efforts to develop therapeutic candidates that envelop the potential health benefits of the marijuana plant.

To view the full publication, visit: https://www.networknewswire.com/innovation-dr...-biotechs/

" InMed Pharmaceuticals, Inc. ( CSE : IN ) ( OTCQB : IMLFF ) ... has several cannabinoid-based drug candidates in its pipeline. The company has also developed a proprietary and groundbreaking technology for the biosynthesis of all 90+ cannabinoids via an innovative process that enables a wide spectrum of drug development activities in-house, from drug manufacture to novel, tissue-specific formulation and all clinical and regulatory work. Though currently valued at only US$81 million, InMed's capabilities position it among the ranks of larger biotechs with important innovations in this industry...

"InMed's innovative approach to bioinformatics and biosynthesis is groundbreaking, and the company has already filed a provisional patent to protect its cannabinoid biosynthetic process. InMed is currently working on scaling up its manufacturing capability, pivoting from the success of its proprietary laboratory-based systems. To assist with its advancing position in the market, InMed engaged as a consultant Ben Paterson, P.E., a professional engineer with extensive experience in the development of purification and manufacturing processes in the pharmaceutical industry ( http://nnw.fm/9Bzoh )."

About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit www.inmedpharma.com .

About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.